Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dagliflozin for prevention of atrial arrhythmia recurrence after atrial fibrillation catheter ablation
ChiCTR2300074988Phase 4Recruiting
- Sponsor
- Changhai Hospital
- Start
- Sep 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of dapagliflozin in Atrial fibrillation (AFib) (2 arms), sponsored by Changhai Hospital. Primary endpoints: Recurrence of atrial arrhythmias on days 91-365 after catheter ablation and 1-year atrial arrhythmia burden after atrial fibrillation catheter ablation. Started Sep 2023; status: recruiting.
02
Drugs
dapagliflozin
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on ChiCTR2300074988.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300074988.